How many drugs treat Acute lymphoid leukemia?

Drug Landscape tracks 10 marketed treatments for Acute lymphoid leukemia (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/acute-lymphoid-leukemia.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

Acute lymphoid leukemia — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Acute lymphoid leukemia (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Acute lymphoid leukemia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Erwinase	CRISANTASPASE	Jazz Pharms Inc			2011-01-01
Clolar	CLOFARABINE	Sanofi	Nucleoside Metabolic Inhibitor [EPC]	Ribonucleoside-diphosphate reductase large subunit	2004-01-01
Elspar	ASPARAGINASE	Merck & Co.	Asparagine-specific Enzyme [EPC]	L-asparagine	1994-01-01
Daunorubicin Hydrochloride	daunorubicin	Meiji Seika Pharma Co., Ltd	Anthracycline Topoisomerase Inhibitor	Histone deacetylase 6	1979-01-01
Doxorubicin Hydrochloride	doxorubicin	Pfizer	Anthracycline Topoisomerase Inhibitor	Aurora kinase A	1974-01-01
Liposomal Doxorubicin	liposomal-doxorubicin	Pfizer	doxorubicin	72 kDa type IV collagenase	1974-01-01
Cytarabine	Cytarabine	Nippon Shinyaku Co., Ltd.	Antimetabolite	DNA polymerase	1969-01-01
Oncovin	vincristine	Pfizer Inc.	Vinca Alkaloid	Canalicular multispecific organic anion transporter 1	1963-01-01
Oncovin	Vincristine Sulfate	Pfizer Inc.	Vinca Alkaloid	Canalicular multispecific organic anion transporter 1	1963-01-01
Decadron	dexamethasone	Generic (originally Merck)	Corticosteroid [EPC]	Annexin A1, Interleukin-4, Androgen receptor	1958-10-30

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 5 drugs in Acute lymphoid leukemia
Pfizer · 4 drugs in Acute lymphoid leukemia
Pfizer Inc. · 3 drugs in Acute lymphoid leukemia
University of Colorado, Denver · 2 drugs in Acute lymphoid leukemia
Generic (originally Schering) · 2 drugs in Acute lymphoid leukemia
Generic (originally Merck) · 1 drug in Acute lymphoid leukemia
Generic (originally Lederle Laboratories) · 1 drug in Acute lymphoid leukemia
Biocad · 1 drug in Acute lymphoid leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto · 1 drug in Acute lymphoid leukemia
Generic (originally Upjohn/Pfizer) · 1 drug in Acute lymphoid leukemia
Hannover Medical School · 1 drug in Acute lymphoid leukemia
Dana-Farber Cancer Institute · 1 drug in Acute lymphoid leukemia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Acute lymphoid leukemia:

Cite this brief

Drug Landscape (2026). Acute lymphoid leukemia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/acute-lymphoid-leukemia. Accessed 2026-06-09.

Acute lymphoid leukemia full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing